Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.BRAF alterations are less common in non-colorectal gastrointestinal (GI) cancers than in colorectal cancer (CRC), but show distinct patterns, including more frequent fusions. Further research is needed to understand the clinical impact of these BRAF alterations in non-CRC GI malignancies.
Area Of Science
- Oncology
- Genetics
- Gastroenterology
Background
- The role of BRAF alterations in colorectal cancer (CRC) is established, but their characterization in other gastrointestinal (GI) malignancies is limited.
- This study investigates the frequency and spectrum of BRAF alterations in non-CRC GI cancers.
Purpose Of The Study
- To determine the prevalence and types of BRAF alterations in non-CRC GI malignancies.
- To compare BRAF alteration profiles between CRC and non-CRC GI malignancies.
Main Methods
- Somatic tumor profiling (tissue-based or liquid-based) was performed on patients with CRC and non-CRC GI malignancies.
- Gain-of-function (GOF) BRAF alterations were defined as pathogenic/likely pathogenic short variants, copy number amplifications (≥8), or fusions (RNA or DNA).
Main Results
- BRAF GOF alterations were found in 8.9% of CRC and 2.2% of non-CRC GI malignancies.
- Bile duct and small intestine cancers showed the highest prevalence of BRAF GOF alterations (4.1% and 4.0%, respectively).
- Non-CRC GI malignancies had a higher frequency of class II and III BRAF alterations, including a notable incidence of BRAF fusions (12% in non-CRC vs. 2.2% in CRC).
Conclusions
- Non-CRC GI malignancies exhibit a distinct BRAF alteration profile compared to CRC, characterized by a higher rate of class II/III mutations and BRAF fusions.
- The clinical significance of BRAF alterations, particularly fusions, in non-CRC GI cancers warrants further investigation for potential therapeutic implications.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...